Mereo BioPharma Group (MREO) Fundamentals 2026 — Revenue Analysis | SniperIQ
Mereo BioPharma Group (MREO) is a GB-listed Healthcare company in Biotechnology with a market capitalization of $48M, trading at $0.30 on the NASDAQ. This SniperIQ fundamentals page covers Mereo BioPharma Group's valuation, profitability (net margin -7139.7%), revenue ($500,000 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Mereo BioPharma Group's market cap?
Mereo BioPharma Group (MREO) has a market capitalization of approximately $48M, trading at $0.30 on the NASDAQ. Market cap moves with the live share price.
What is Mereo BioPharma Group's P/E ratio?
Mereo BioPharma Group's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Mereo BioPharma Group?
Mereo BioPharma Group runs a net profit margin of -7139.7%, a gross margin of -105.7%, and an operating margin of -7531.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Mereo BioPharma Group generate?
Mereo BioPharma Group reported revenue of $500,000 for fiscal year 2025, with net income of -$42M and earnings per share (EPS) of -0.26. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Mereo BioPharma Group pay a dividend?
Mereo BioPharma Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Mereo BioPharma Group financially healthy?
Mereo BioPharma Group carries a debt-to-equity ratio of 0.00x and a current ratio of 6.48x, with a market beta of 0.29. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Mereo BioPharma Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Mereo BioPharma Group (MREO) the key facts are: market cap $48M, revenue $500,000, 52-week range 0.2-2.37. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Mereo BioPharma Group's full fundamentals live
Get Mereo BioPharma Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.